In the AFFIRM trial, elderly patients (mean age, 70; 61% men) with minimally symptomatic atrial fibrillation (AF) and high risk for stroke were randomized to either a rate-control or a rhythm ...

Treatment plans for AFib may include a combination of several medications, including beta blockers (like Lopressor, or metoprolol) or calcium channel blockers (such as Verelan, or verapamil) to ...

The results will support the company’s application for expanded labeling of its popular Farapulse pulsed field ablation system in a larger group of patients with atrial fibrillation.

Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Boston Scientific Corp. reported positive data for two key atrial fibrillation therapies at AF Symposium 2025 on January 17.

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor with much lower safety risks compared with a direct oral anticoagulant (DOAC), ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

Subcutaneous injection of abelacimab results in lower levels of free factor XI and significantly fewer bleeding even ...